(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 9.9% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 281.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.59%.
Organogenesis Holdings's revenue in 2025 is $465,218,000.On average, 4 Wall Street analysts forecast ORGO's revenue for 2025 to be $66,155,492,260, with the lowest ORGO revenue forecast at $63,456,071,000, and the highest ORGO revenue forecast at $68,215,276,325. On average, 4 Wall Street analysts forecast ORGO's revenue for 2026 to be $70,343,592,946, with the lowest ORGO revenue forecast at $66,627,605,429, and the highest ORGO revenue forecast at $73,438,980,090.
In 2027, ORGO is forecast to generate $77,424,021,349 in revenue, with the lowest revenue forecast at $74,300,713,534 and the highest revenue forecast at $79,794,740,161.